Figure 2: Cholesterol is synthesized in the endoplasmic reticulum and cytosolic segments
FIGURE 3
Figure 3: NPC1
FIGURE 4
Figure 4: A) Immunofluorescence staining of mouse NPC1L1 in the gallbladder of wild-type (WT) and L1KO mice on regular chow diet using a rabbit Anti-NPC1L1 Antibody (aa1000–1100) IHC-plus LS-B88 (LifeSpan BioSciences, Inc., Seattle, WA). White arrows denote the luminal surface of gallbladder epithelium. B) Immunoblots of mouse NPC1L1 in the 100µg of gallbladder homogenates of WT and L1KO mice using the above antibody. C) Immunoblots of human NPC1L1 in the homogenates (30µg protein each) of the 5 equal segments of small intestine (SI: 1–5). Two L1-KO mouse livers as negative controls (Neg., 20µg). The L1KO liver transgenically overexpressing human NPC1L1 as a positive control (Pos., 20µg). In the bottom panel, 50µg homogenate proteins were used for stomach, kidney and liver, and 20µg for intestine (jejunum). 1, DKO; 2, DKO/IntOnly. D) Intestinal cholesterol absorption (n = 8). E) Fecal neutral sterol excretion (n = 8–12). F) Immunoblots of ABCG5 and receptor-associated protein (RAP) (as a loading control) in the jejunal membrane preparations. G) Relative mRNA levels of cholesterol-sensitive genes in the jejuna (n = 5). Groups not sharing a common superscript letter are significantly different (P < 0.05). Ezet, ezetimibe; HMGCR, HMG-CoA reductase; HMGCS, HMG-CoA synthase [18-20].
Figures at a glance